IceCure Medical Ltd. has announced two new publications from the independent THERMAC Trial featuring its ProSense® cryoablation system for early-stage breast cancer. The trial, conducted in the Netherlands, compared different thermal ablation methods, with ProSense® demonstrating the highest complete ablation rate without adverse events. The first article, published in the European Journal of Surgical Oncology, reported that 95% of patients were satisfied with the cosmetic outcomes of ProSense® cryoablation. The second article, published in Radiology, highlighted its superior performance compared to other thermal ablation techniques. These findings were previously presented at several medical conferences, including the European Conference on Interventional Oncology 2025 and the Society of Interventional Oncology 2025 Annual Meeting. The THERMAC Trial's phase II results suggest that cryoablation with ProSense® is the preferred technique for future comparisons with surgery in a phase III trial.